Valuation: Definium Therapeutics, Inc.

Market Cap 4.86B 4.26B 4.03B 3.67B 6.87B 466B 6.92B 48.2B 18.67B 238B 18.25B 17.85B 765B P/E 2026 *
-11.4x
P/E 2027 * -18.1x
Enterprise Value 3.83B 3.36B 3.17B 2.89B 5.41B 367B 5.45B 37.98B 14.71B 188B 14.38B 14.07B 603B EV / Sales 2026 *
-
EV / Sales 2027 * 128x
Free-Float
97.98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Definium Therapeutics, Inc.

1 day-1.52%
1 week-6.80%
Current month-8.94%
1 month-19.28%
3 months-19.25%
6 months+95.83%
Current year+170.13%
1 week 35.89
Extreme 35.89
40.39
1 month 35.89
Extreme 35.89
44.97
Current year 12.88
Extreme 12.882
49.7
1 year 10.46
Extreme 10.4646
49.7
3 years 2.41
Extreme 2.41
49.7
5 years 2.12
Extreme 2.12
49.7
10 years 1.25
Extreme 1.249499
86.55
Manager TitleAgeSince
Chief Executive Officer 37 2021-06-08
Director of Finance/CFO 52 2025-06-01
Chief Tech/Sci/R&D Officer 46 2021-01-31
Director TitleAgeSince
Director/Board Member 37 2021-12-12
Director/Board Member 67 2021-09-28
Chairman 69 2021-12-12
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Exercice

Director

3,258 0.0025%
9/18/26 Exercice

Chairman

2,172 0.0016%
9/14/26 Free

General Counsel

125,000 0.0942%
Change 5-day change 1-year change 3-year change Capi.($)
-1.52%-6.80%+270.21%+907.52% 4.86B
-0.14%+4.33%+9.88%+31.73% 47.97B
-1.69%+1.48%+53.02%+33.59% 44.5B
+2.56%+7.34%+382.17%+594.81% 43.93B
+0.24%+2.85%+9.78%+89.54% 41.03B
-0.62%-1.11%+4.70%+46.02% 29.85B
-0.28%+1.07%+26.83%+152.91% 17.27B
-0.46%+1.20%+26.78%+41.32% 15.3B
-2.21%-4.70% - - 14.82B
+3.37%+9.21%+9.93% - 15.34B
Average -0.08%+1.44%+88.15%+237.18% 27.49B
Weighted average by Cap. +0.08%+2.69%+86.53%+171.13%

Financials

2026 *2027 *
Net sales - 31.42M 27.57M 26.04M 23.73M 44.42M 3.01B 44.74M 312M 121M 1.54B 118M 115M 4.94B
Net income -376M -330M -312M -284M -532M -36.03B -535M -3.73B -1.44B -18.41B -1.41B -1.38B -59.16B -272M -238M -225M -205M -384M -26.03B -387M -2.69B -1.04B -13.3B -1.02B -998M -42.73B
Net Debt -1.03B -904M -854M -778M -1.46B -98.79B -1.47B -10.22B -3.96B -50.47B -3.87B -3.79B -162B -832M -730M -689M -628M -1.18B -79.72B -1.18B -8.25B -3.19B -40.73B -3.12B -3.06B -131B
Logo Definium Therapeutics, Inc.
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
Employees
-
Date Price Change Volume
26-09-25 US$36.17 -1.52% 2,682,911
26-09-24 US$36.73 -2.44% 2,308,995
26-09-23 US$37.65 -6.62% 2,712,783
26-09-22 US$40.32 +2.65% 1,753,534
26-09-21 US$39.28 +1.21% 2,038,015
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
36.17USD
Average target price
71.65USD
Spread / Average Target
+98.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DFTX Stock